Reported 1 day ago
At the JPMorgan Healthcare Conference in San Francisco, dealmakers are optimistic about a resurgence in healthcare mergers and acquisitions (M&A) exceeding $10 billion, fueled by less anticipated antitrust scrutiny under President-elect Donald Trump. Following a significant decline in deal activity during the previous year, marked by no biopharma transactions over $5 billion, executives see potential for recovery, evidenced by Johnson & Johnson's recent $14.6 billion acquisition of Intra-Cellular Therapies. While some express caution, anticipating it may take over a year for M&A activity to rebound to pre-pandemic levels, a pro-business stance from the incoming administration could unlock previously shelved deals.
Source: YAHOO